Background Randomized trials have shown that the transplantation of filgrastim-mobilized
peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases …

Background and Methods It is uncertain whether mortality rates among patients who have
undergone bone marrow transplantation return to the level of the mortality rates of the general …

Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were
evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from …

Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed
in the United States annually. With advances in transplantation technology and supportive …

Background Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma)
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …

Although transplant practices have changed over the last decades, no information is available
on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over …

We analyzed the outcome of 692 patients with severe aplastic anemia (SAA) receiving
transplants from HLA-matched siblings. A total of 134 grafts were peripheral blood progenitor cell (…

Cytokine-mobilized peripheral blood is increasingly used instead of bone marrow as the source
of cells for allogeneic transplantation. Although cells lead to faster hematologic recovery, …

Background Strong immunosuppression, including chemotherapy and immune-depleting
antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has been …

Allogeneic hematopoietic stem cell transplantation is the only curative therapy for
myelodysplasia (MDS). To identify factors influencing transplantation outcome, we studied 452 …